IL-21 blockade—a new therapeutic approach for psoriasis?
نویسندگان
چکیده
منابع مشابه
a new approach to credibility premium for zero-inflated poisson models for panel data
هدف اصلی از این تحقیق به دست آوردن و مقایسه حق بیمه باورمندی در مدل های شمارشی گزارش نشده برای داده های طولی می باشد. در این تحقیق حق بیمه های پبش گویی بر اساس توابع ضرر مربع خطا و نمایی محاسبه شده و با هم مقایسه می شود. تمایل به گرفتن پاداش و جایزه یکی از دلایل مهم برای گزارش ندادن تصادفات می باشد و افراد برای استفاده از تخفیف اغلب از گزارش تصادفات با هزینه پائین خودداری می کنند، در این تحقیق ...
15 صفحه اولTherapeutic implications of IL-17A blockade in psoriasis.
The discovery of T helper type 17 lymphocytes in 2005 represented an important advance in understanding the immunopathogenesis of immunologically mediated inflammatory diseases, by identifying an important source of cytokine IL-17A, whose role in autoimmune diseases has been identified in experimental models. Over 15 years ago, the role of IL-17A in the pathogenesis of psoriasis and its proinfl...
متن کاملIL-17A, IL-22, IL-6, and IL-21 Serum Levels in Plaque-Type Psoriasis in Brazilian Patients
Psoriasis is a chronic inflammatory skin disease characterized by alterations in cytokines produced by both Th1 and Th17 pathways. The aim of this study was to evaluate serum levels of pivotal cytokines and correlate them with clinical parameters. Serum samples from 53 psoriasis patients and 35 healthy volunteers, matched by the proportion of sex and age ratios, were collected for ELISA cytokin...
متن کاملFK 506: a new therapeutic agent for severe recalcitrant psoriasis.
BETWEEN 12 and 18 months ago we treated three patients with FK S06 who had severe psoriasis that was refractory to conventionai therapy and four patients with w,despread incidental psonasis before undergoing hean or liver transplantation under FK 506. All had dramatic resolution of psonasis. which remaIned in remission as long as full-dose therapy was provided. Serial skin biopsies had a rapid ...
متن کاملInterleukin (IL)-33: new therapeutic target for atopic diseases.
Interleukin (IL)-33, a member of the IL-1 family of cytokines, is produced when epithelial and endothelial cells are exposed to stimuli. Hematopoietic cells such as macrophages also produce IL-33. IL-33 is considered to function as an 'alarmin', activating various immune cells through its receptor ST2, which leads to the production of various molecules. The IL-33-induced production of pro-infla...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature Reviews Rheumatology
سال: 2009
ISSN: 1759-4790,1759-4804
DOI: 10.1038/nrrheum.2009.202